- Home
- TLSA vs MAIA Comparison
TLSA vs MAIA Comparison
Compare TLSA & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- MAIA
- Stock Information
- Founded
- TLSA 2013
- MAIA 2018
- Country
- TLSA United Kingdom
- MAIA United States
- Employees
- TLSA N/A
- MAIA N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- MAIA Health Care
- Exchange
- TLSA Nasdaq
- MAIA Nasdaq
- Market Cap
- TLSA 187.0M
- MAIA 46.7M
- IPO Year
- TLSA 2000
- MAIA 2022
- Fundamental
- Price
- TLSA $1.45
- MAIA $1.88
- Analyst Decision
- TLSA
- MAIA
- Analyst Count
- TLSA 0
- MAIA 0
- Target Price
- TLSA N/A
- MAIA N/A
- AVG Volume (30 Days)
- TLSA 246.7K
- MAIA 529.1K
- Earning Date
- TLSA 07-22-2025
- MAIA 08-08-2025
- Dividend Yield
- TLSA N/A
- MAIA N/A
- EPS Growth
- TLSA N/A
- MAIA N/A
- EPS
- TLSA N/A
- MAIA N/A
- Revenue
- TLSA N/A
- MAIA N/A
- Revenue This Year
- TLSA N/A
- MAIA N/A
- Revenue Next Year
- TLSA N/A
- MAIA N/A
- P/E Ratio
- TLSA N/A
- MAIA N/A
- Revenue Growth
- TLSA N/A
- MAIA N/A
- 52 Week Low
- TLSA $0.63
- MAIA $1.40
- 52 Week High
- TLSA $1.91
- MAIA $4.24
- Technical
- Relative Strength Index (RSI)
- TLSA 48.43
- MAIA 56.41
- Support Level
- TLSA $1.43
- MAIA $1.80
- Resistance Level
- TLSA $1.81
- MAIA $2.15
- Average True Range (ATR)
- TLSA 0.09
- MAIA 0.13
- MACD
- TLSA -0.02
- MAIA 0.02
- Stochastic Oscillator
- TLSA 18.53
- MAIA 60.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.